ALIVUS

Alivus Life Sciences Share Price

 

 

Invest in Alivus Life Sciences with 3.07X leverage

Invest with MTF

Performance

  • Low
  • ₹904
  • High
  • ₹932
  • 52 Week Low
  • ₹850
  • 52 Week High
  • ₹1,251
  • Open Price₹925
  • Previous Close₹891
  • Volume158,323

Investment Returns

  • Over 1 Month -1.96%
  • Over 3 Month -3.76%
  • Over 6 Month -17.64%
  • Over 1 Year -16.67%

Smart Investing Starts Here Start SIP with Alivus Life Sciences for Steady Growth!

Invest Now

Alivus Life Sciences Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

  • P/E Ratio
  • 21.2
  • PEG Ratio
  • 0.8
  • Market Cap Cr
  • 11,226
  • P/B Ratio
  • 4
  • Average True Range
  • 23.82
  • EPS
  • 43.23
  • Dividend Yield
  • 0.5
  • MACD Signal
  • -9.87
  • RSI
  • 47.16
  • MFI
  • 16.72

Alivus Life Sciences Financials

Alivus Life Sciences Technicals

EMA & SMA

Current Price
₹915.05
+ 24.55 (2.76%)
pointer
  • Bearish Moving Average 11
  • Bullish Moving Average 5
  • 20 Day
  • ₹917.79
  • 50 Day
  • ₹937.22
  • 100 Day
  • ₹964.10
  • 200 Day
  • ₹985.49

Resistance and Support

916.98 Pivot Speed
  • R3 958.17
  • R2 945.08
  • R1 930.07
  • S1 901.97
  • S2 888.88
  • S3 873.87

Ratings

Master Rating

EPS Strenth

Price Strength

Buyer Demand

Group Rank

Glenmark Life Sciences develops and manufactures high-quality Active Pharmaceutical Ingredients (APIs), supplying over 130 molecules to more than 700 global pharmaceutical companies. With world-class manufacturing and research capabilities, GLS focuses on operational excellence, regulatory compliance, and innovation.

Alivus Life Sciences Limited has an operating revenue of Rs. 2,481.22 Cr. on a trailing 12-month basis. An annual revenue growth of 5% is not great, Pre-tax margin of 27% is great, ROE of 17% is exceptional. The company is debt free and has a strong balance sheet enabling it to report stable earnings growth across business cycles. The stock from a technical standpoint is trading below to its key moving averages. It needs to take out these levels and stay above it to make any meaningful move. From an O'Neil Methodology perspective, the stock has an EPS Rank of 71 which is a FAIR score but needs to improve its earnings, a RS Rating of 24 which is POOR indicating the underperformance as compared to other stocks, Buyer Demand at C+ which is evident from recent supply seen, Group Rank of 145 indicates it belongs to a poor industry group of Medical-Ethical Drugs and a Master Score of C is fair but needs to improve. Institutional holding has declined in the last reported quarter is a negative sign. Overall, the stock has mediocre earnings and technical strength, there are superior stocks in the current market environment.

Disclaimer: This stock analysis report is algorithmically generated for informational purposes only and should not be considered as a buy or sell recommendation.

View More

Alivus Life Sciences Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2025-11-06 Quarterly Results
2025-08-01 Quarterly Results
2025-05-15 Audited Results & Final Dividend
2025-01-23 Quarterly Results
2024-10-24 Quarterly Results
Date Purpose Remarks
2025-09-01 FINAL Rs.5.00 per share(250%)Final Dividend
2023-10-17 INTERIM Rs.22.50 per share(1125%)Interim Dividend
2023-03-24 INTERIM Rs.21.00 per share(1050%)Interim Dividend
2021-11-23 INTERIM Rs.10.50 per share(525%)Interim Dividend
View Alivus Life Sciences Dividend History Arrow

Alivus Life Sciences F&O

Alivus Life Sciences Shareholding Pattern

74.91%
3.87%
0.24%
6.84%
0%
10.14%
4%

About Alivus Life Sciences

  • NSE Symbol
  • ALIVUS
  • BSE Symbol
  • 543322
  • Managing Director & CEO
  • Dr. Yasir Rawjee
  • ISIN
  • INE03Q201024

Similar Stocks to Alivus Life Sciences

Alivus Life Sciences FAQs

Alivus Life Sciences share price is ₹915 As on 08 November, 2025 | 06:35

The Market Cap of Alivus Life Sciences is ₹11226 Cr As on 08 November, 2025 | 06:35

The P/E ratio of Alivus Life Sciences is 21.2 As on 08 November, 2025 | 06:35

The PB ratio of Alivus Life Sciences is 4 As on 08 November, 2025 | 06:35

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91

By proceeding, you agree to all T&C*

footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23